Advertisement

Journal of Inherited Metabolic Disease

, Volume 34, Issue 5, pp 1053–1059 | Cite as

Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool

  • Elin Haf Davies
  • Eugen Mengel
  • Anna Tylki-Szymanska
  • G. Kleinotiene
  • Joerg Reinke
  • Ashok Vellodi
Original Article

Abstract

In 2007, the European Task Force for neuronopathic Gaucher disease (NGD) published a review of 55 patients across four countries. Although some observations were possible, analysis was difficult due to the absence of a systematic way of assessing patients. In response to this, a Severity Scoring Tool (SST) was devised to offer a systematic means of assessing the neurological presentation seen. The SST has been modified (mSST) and is a valid tool for monitoring neurological progression. This review describes disease status and progression of neurological manifestations in a cohort of 39 chronic NGD patients across three European countries over a period of 4 years, using the mSST.

Keywords

Enzyme Replacement Therapy Original Review Substrate Reduction Therapy Neuronopathic Gauche Disease Task Force Guideline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

This work was made possible by grants from the Gaucher Association UK and Genzyme. Thank you also to the international experts who took part in the discussion to modify the SST: Amal El Beshlawy, Egypt; B. Bembi, Italy; Edward Giannini, USA; Thong Meow Keong, Malaysia; Ana Maria Martins, Brazil; A Tylki-Szymanska, Poland; Ashok Vellodi, UK.

References

  1. Davies E, Erikson A, Collin-Histed T, Mengel E, Tylki-Szymanska A, Vellodi A (2007a) Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J Inherit Metab Dis 30(6):935–42PubMedCrossRefGoogle Scholar
  2. Davies E, Surtees R, DeVile C, Schoon I, Vellodi A (2007b) A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 30(5):768–82. 5, Epub 2007 Sep 16PubMedCrossRefGoogle Scholar
  3. Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, van Schaik I, Timmons M, Ries M, Vellodi A (2008) A randomized controlled trial of miglustat in Gaucher disease type 3. Ann Neurol 64(5):514–22PubMedCrossRefGoogle Scholar
  4. Tylki-Szymańska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E (2010) Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis 33(4):339–46PubMedCrossRefGoogle Scholar
  5. Vellodi A, Bembi B, de Villemeur TB, Collin-Histed T, Erikson A, Mengel E, Rolfs A, Tylki-Szymanska A (2001) Neuronopathic Gaucher Disease Task Force of the European Working Group on Gaucher Disease. 2001 Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24(3):319–27PubMedCrossRefGoogle Scholar
  6. Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T, Mengel E, Erikson A, Schiffmann R (2009) Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 32(5):660–4, Aug 5PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2011

Authors and Affiliations

  • Elin Haf Davies
    • 1
  • Eugen Mengel
    • 2
  • Anna Tylki-Szymanska
    • 3
  • G. Kleinotiene
    • 4
  • Joerg Reinke
    • 2
  • Ashok Vellodi
    • 5
  1. 1.Institute of Child HealthLondonUK
  2. 2.Villa Metabolica Childrens HospitalUniversitatsmedizin, MainzLangenbeckstrGermany
  3. 3.The Children’s Memorial Health InstituteWarsawPoland
  4. 4.Vilnius University Children’s HospitalVilniusLithuania
  5. 5.Great Ormond St Hospital for Children NHS TrustLondonUK

Personalised recommendations